These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 18374589)

  • 1. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer.
    Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J
    J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of 18-FDG uptake in early stage NSCLC.
    Chen JC; Huang TW; Cheng YL; Chang H; Tzao C; Huang WS; Lee SC
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):413-6. PubMed ID: 19795329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
    Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
    Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
    Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
    J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
    Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
    Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The variation of prognostic significance of Maximum Standardized Uptake Value of [18F]-fluoro-2-deoxy-glucose positron emission tomography in different histological subtypes and pathological stages of surgically resected Non-Small Cell Lung Carcinoma.
    Casali C; Cucca M; Rossi G; Barbieri F; Iacuzio L; Bagni B; Uliano M
    Lung Cancer; 2010 Aug; 69(2):187-93. PubMed ID: 19942313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New positron emission tomography derived parameters as predictive factors for recurrence in resected stage I non-small cell lung cancer.
    Melloni G; Gajate AM; Sestini S; Gallivanone F; Bandiera A; Landoni C; Muriana P; Gianolli L; Zannini P
    Eur J Surg Oncol; 2013 Nov; 39(11):1254-61. PubMed ID: 23948705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formula corrected maximal standardized uptake value in FDG-PET for partial volume effect and motion artifact is not a prognostic factor in stage I non-small cell lung cancer treated with stereotactic body radiotherapy.
    Yamamoto T; Kadoya N; Shirata Y; Kaneta T; Koto M; Umezawa R; Ishikawa Y; Kubozono M; Sugawara T; Matsushita H; Abe K; Takeda K; Jingu K
    Ann Nucl Med; 2015 Oct; 29(8):666-73. PubMed ID: 26040413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18F-Fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer.
    Li L; Hu M; Zhu H; Zhao W; Yang G; Yu J
    Clin Lung Cancer; 2010 Sep; 11(5):335-40. PubMed ID: 20837459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study.
    de Jong WK; van der Heijden HF; Pruim J; Dalesio O; Oyen WJ; Groen HJ
    J Thorac Oncol; 2007 Nov; 2(11):1007-12. PubMed ID: 17975491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Total lesion glycolysis by 18F-FDG PET/CT is independent prognostic factor in patients with advanced non-small cell lung cancer.
    Yıldırım F; Yurdakul AS; Özkaya S; Akdemir ÜÖ; Öztürk C
    Clin Respir J; 2017 Sep; 11(5):602-611. PubMed ID: 26434685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
    Kwon W; Howard BA; Herndon JE; Patz EF
    J Thorac Oncol; 2015 Jun; 10(6):897-902. PubMed ID: 25811445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer.
    Higashi K; Ueda Y; Arisaka Y; Sakuma T; Nambu Y; Oguchi M; Seki H; Taki S; Tonami H; Yamamoto I
    J Nucl Med; 2002 Jan; 43(1):39-45. PubMed ID: 11801701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET maximum standardized uptake value is prognostic for recurrence and survival after stereotactic body radiotherapy for non-small cell lung cancer.
    Kohutek ZA; Wu AJ; Zhang Z; Foster A; Din SU; Yorke ED; Downey R; Rosenzweig KE; Weber WA; Rimner A
    Lung Cancer; 2015 Aug; 89(2):115-20. PubMed ID: 26078260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
    Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
    Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
    Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
    AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of SUVmax measurements obtained by FDG-PET in patients with non-small cell lung cancer receiving chemotherapy.
    Imamura Y; Azuma K; Kurata S; Hattori S; Sasada T; Kinoshita T; Okamoto M; Kawayama T; Kaida H; Ishibashi M; Aizawa H
    Lung Cancer; 2011 Jan; 71(1):49-54. PubMed ID: 20430470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.